Overview of the drug development pipeline for gastritis
Gastritis is the inflammation of gastric mucosa, which is a membrane lining that covers the surface of internal organs and body cavities. The production of mucus, acid, and enzymes reduces when the inflammation of the stomach lining takes place. Acute gastritis and choric gastritis are the two types of gastritis conditions that people suffer from. Gastritis patients experience upper abdominal discomfort, vomiting, nausea, and dyspepsia symptoms including bloating, heartburn, and regurgitation. Technavio’s market research analysts have predicted that with the introduction of endoscopy with a biopsy of the stomach, blood test, tool test, and test for the presence of Helicobacter pylori infection as some of the most promising approach to diagnose gastritis, the global gastritis market will witness growth in the forthcoming years.
According to this pipeline analysis report, most of the drug development molecules in the pipeline available are associated with the acute and chronic gastric inflammation. This type of inflammation refers to sudden swelling or inflammation in the stomach lining.
Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of gastritis. According to the gastritis industry analysis research report, in addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- Trio Medicines
- RedHill
- Daewoong
Therapeutic assessment of the drug development pipeline for gastritis by route of administration
- Oral
- Unspecified
Based on the gastritis industry insights, the oral route of administration (ROA) involves the administration of drug substances through a mouth cavity. It has been observed that the majority of total molecules for gastritis are associated with the oral administration.
Therapeutic assessment of the drug development pipeline for gastritis by therapeutic modalities
- Small molecules
- Biomolecules
According to this gastritis market forecast, the majority of the molecules that are currently in the drug development pipeline for gastritis are being developed as small molecules. These molecules are chemically manufactured active substances that are able to enter the cells easily due to their low molecular weight.
Key questions answered in the report include
- What are the drug development molecules in the various development stages of gastritis?
- What are the companies that are currently involved in the development of drug molecules for gastritis?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.